Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vir Biotechnology, Inc. - Common Stock (NQ:VIR)

5.430 -0.170 (-3.04%)
Streaming Delayed Price Updated: 9:30 AM EST, Nov 4, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vir Biotechnology, Inc. - Common Stock

< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Glaxo - Vir Biotech's COVID Treatment Approved In Japan
Japan's health ministry expert committee has approved GlaxoSmithKline Plc (NYSE: GSK) - Vir Biotechnology Inc's (NASDAQ: VIR) sotrovimab, a COVID-19... 
Via Benzinga
Why Vir Biotechnology Stock Is Sinking This Week
Shares fell after an analyst's downgrade. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For September 22, 2021
Upgrades Argus Research upgraded the previous rating for Simon Property Group Inc (NYSE: 
Via Benzinga
Unusual Options Activity Insight: Vir Biotechnology
Shares of Vir Biotechnology (NASDAQ:VIR) saw some unusual ... 
Via Benzinga
The Daily Biotech Pulse: Pfizer, Bristol-Myers Squibb Earnings, Amgen Goes Shopping, GlaxoSmithKline-Vir's COVID-19 Antibody Treatment Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 27) Bio-Rad Laboratories, Inc... 
Via Benzinga
Vir Biotechnology Earnings Perspective: Return On Capital Employed
According to Benzinga Pro, during Q2, Vir Biotechnology (NASDAQ:VIR) earned $61.02 million, a 138.46% increase from the preceding quarter. Vir Biotechnology also posted a total of... 
Via Benzinga
Now May Be the Big Moment for These 2 COVID Stocks
Their products are seeing a surge in demand. 
Via The Motley Fool
9 Health Care Stocks With Unusual Options Alerts In Today's Session
This unusual options alert can help traders discover the next big trading opportunities. Traders will search for circumstances when the market estimation of an option diverges... 
Via Benzinga
Vir Biotech-GSK's COVID-19 Treatment Wins Provisional Approval In Australia
The Australian Therapeutic Goods Administration has granted provisional marketing authorization for Vir Biotechnology Inc's (NASDAQ: VIR) for sotrovimab,... 
Via Benzinga
3 Vaccine Stocks for the Next Decade
Because of COVID-19, vaccine stocks have been fantastic investments over the last couple of years. What should investors expect over the next 10 years? 
Via The Motley Fool
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell • OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million. •... 
Via Benzinga
European Commission To Procure 220K Doses Of Glaxo-Vir Biotech's COVID-19 Antibody
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of... 
Via Benzinga
Vir Biotechnology Starts Dosing In Mid-Stage Hepatitis B Trial With Combination Therapy
Vir Biotechnology Inc (NASDAQ: VIR) has dosed the first patient in the Phase 2 MARCH trial evaluating VIR-2218 in combination with VIR-3434 to treat patients with... 
Via Benzinga
GlaxoSmithKline's and Vir's Latest COVID Therapy Results: What Investors Should Know
The sample size was small, but the results were impressive. 
Via The Motley Fool
EC Selects Antibody Therapies, Arthritis Drug As Preferred COVID-19 Meds: Reuters
The European Commission (EC) picked four antibody treatments and a repurposed Eli Lilly And Co's (NYSE: LLY) rheumatoid arthritis drug for an initial... 
Via Benzinga
Vir Biotech's HBV Candidates Show Positive Safety Profiles
Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic... 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Gainers Osmotica Pharmaceuticals (NASDAQ:OSMT) stock increased by 39.78% to $3.97 during Friday's regular session. The current volume of 48.4 million shares is 18988.... 
Via Benzinga
The Daily Biotech Pulse: Roche Gets Authorization For COVID-19 Treatment, Nods For Sanofi-Regeneron In Europe, Osmotica Divestment, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 24) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
Dual-Antibody Cocktail Shows Effectiveness In COVID-19 Animal Models: Reuters
In mice and hamster study, COVID-19 therapies comprising two types of antibodies were found to be effective against a wide range of COVID-19 variants, Reuters reported ... 
Via Benzinga
The Daily Biotech Pulse: Gemini Sinks On Data, Amgen's Migraine Drug Approved In Japan, Liver Congress Gets Underway
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 22) AngioDynamics, Inc. (NASDAQ... 
Via Benzinga
GSK - Vir Biotech's Sotrovimab Reduces Hospitalization, Risk Of Death In Adult COVID-19 Patients
GlaxoSmithKline plc (NYSE: GSK) and Vir Biotechnology Inc (NASDAQ: VIR) have announced final, confirmatory results from the Phase 3 COMET-ICE evaluating... 
Via Benzinga
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. 
Via Talk Markets
The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs
Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal... 
Via Benzinga
15 Words From Vir Biotechnology's CEO May Mean Market Dominance
Vir's antibody treatment is addressing one of the biggest COVID challenges. 
Via The Motley Fool
The Surprising Move Vir Stock Made After Winning Covid Drug Authorization
GlaxoSmithKline and Vir Biotechnology won Food and Drug Administration authorization for a Covid treatment on Wednesday, but Vir stock slipped Thursday. 
Via Investor's Business Daily
The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)... 
Via Benzinga
Vir Biotech Stock Jumps After FDA Emergency Use Approval COVID-19 Antibody Drug
The FDA has given an emergency use authorization (EUA) to COVID-19 antibody treatment developed by Vir Biotechnology Inc (NASDAQ: VIR) and ... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Zosano Pharma (NASDAQ:ZSAN) stock moved upwards by 22.59% to $0.91 during Thursday's pre-market session. The company's market cap stands at $97.3 million.... 
Via Benzinga
24 Stocks Moving in Thursday's Pre-Market Session
Gainers Vertex Energy, Inc. (NASDAQ: VTNR) rose 82% to $3.24 in pre-market trading after the company announced plans to acquire a Alabama refinery and related logistics assets.... 
Via Benzinga
Market Briefing For Thursday, May 27
Dynamics spurring last year's upside, mostly sputtered with sector-rotation since early February. Periodically breadth broadens out slightly and a move in unison occurs, absent sustainability. 
Via Talk Markets
< Previous 1 2
...
8 9 10 11 12 13 14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.